Erebus Analytics identifies which prescribers are in the commercial channel versus 340B-exposed. IQVIA tells you who prescribes. We tell you where margin is at risk.
Your commercial data reveals prescribing volume. It hides margin exposure.
A significant portion of your prescriber base is affiliated with 340B programs—generating discounted revenue. Your targeting data can't distinguish them.
Every major data vendor reports prescription volume. None report 340B exposure at the physician level.
A physician writing 100 scripts in the commercial channel has different margin potential than one writing 100 scripts through 340B. Your reps don't know the difference.
Current workarounds estimate 340B affiliation based on address proximity to registered entities. That approach misses the physicians who actually matter.
Erebus classifies every prescriber into two categories: commercial-channel physicians and 340B-exposed physicians. Built from authoritative government data sources—not address matching.
Individual prescriber classification, not facility-level estimates. Every NPI is mapped to 340B exposure status.
Classifications derived from auditable government records—not probabilistic address matching. Request a sample to validate against your internal data.
Delivered at NPI level with standard identifiers (NPI, name, specialty, practice address) for direct integration with your HCP master data.
Factor 340B exposure into territory planning
Right-size field force to commercial opportunity
Prioritize commercial-channel targets for new products
Understand 340B exposure across your prescriber base
We use proprietary analysis of government healthcare data to identify prescribers affiliated with 340B-registered entities—a signal that's invisible in standard prescription data.
We process Medicare Part D/B prescribing data for your therapeutic area
Each physician is classified using proprietary 340B affiliation analysis—not proximity-based estimates
Request a sample to check our classifications against your internal records
Ranked physician list with 340B exposure classification and complete contact data
Erebus is vendor-agnostic. We do not license, ingest, or redistribute IQVIA, Symphony, or other third-party commercial data.
Our physician-level classifications are built independently from public government sources and are designed to be aligned by customers with their existing datasets inside their own analytics environment.
Erebus classifications are generated using deterministic rules applied to government data sources. Updated regularly; cadence aligned to customer planning cycles upon engagement.
We track changes in physician affiliations over time and refresh classifications accordingly. Customers can validate samples against internal records prior to deployment.
Erebus provides planning and analytical intelligence for commercial strategy, territory design, and resource allocation.
Erebus does not provide physician-level prescribing guidance, messaging recommendations, or direction for individual clinical decision-making.
No PHI. Erebus does not access, process, or store protected health information. Our data sources are publicly available government records.
Comprehensive Medicare prescribing analysis across the pharmaceutical landscape
Every pharma company has prescriber data. None of them know which prescribers have 340B exposure.
We built the data infrastructure needed to address that gap. 580K+ physicians classified by 340B exposure status. Complete contact data. No dashboards, no consulting engagements—just actionable intelligence designed to complement your existing commercial analytics.
Designed for: U.S. pharmaceutical manufacturers with established commercial teams seeking visibility into 340B exposure across their prescriber base.
We'll send you 30 physicians from your therapeutic area—15 commercial-channel and 15 340B-exposed. Check our classifications against your internal records.
Sample includes: NPI, physician name, specialty, primary practice address, 340B exposure classification, and classification rationale.